Promoting Receptor Protein Tyrosine Phosphatase Activity by Targeting Transmembrane Domain Interactions
Promoting Receptor Protein Tyrosine Phosphatase Activity by Targeting Transmembrane Domain Interactions
批准号:
10797721
负责人:
Matthew J Lazzara
金额:
$9.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-20 至 2025-06-30
关键词:
AffectBindingBiologicalBiologyCell LineCellsComplementComputer ModelsDataDevelopmentDimerizationDisease ProgressionEpidermal Growth Factor ReceptorGoalsHealthHeterodimerizationHomodimerizationHumanKnowledgeMass Spectrum AnalysisMeasurementMediatingMethodsModelingMolecularMusOncogenicOutcomePTPRJ genePeptidesPhenotypePhosphorylationPlayPredispositionProtein Tyrosine PhosphataseReceptor Protein-Tyrosine KinasesRegulationReportingResistanceRoleSignal PathwaySignal TransductionStructure-Activity RelationshipSystems BiologyTestingTherapeutically TargetableTransmembrane DomainTyrosine Kinase InhibitorVariantdesigninsightmutantnovel therapeutic interventionprotein expressionreceptortraffickingtumor xenograft
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Below is the original Project Summary to fill this mandatory field
Receptor protein tyrosine phosphatases (RPTPs) play critical signaling regulatory roles in development,
health, and disease progression. Despite the clear importance of RPTPs in signal transduction, very little is
known about the structure-function relationships that underpin the regulation of their activity. The reported
ability of RPTP homodimerization to antagonize their catalytic activity, however, presents potential
opportunities to develop strategies to promote RPTP activity against their oncogenic receptor tyrosine kinase
(RTK) substrates. We recently showed, using PTPRJ/EGFR as a model RPTP/RTK pair, that: (i)
homodimerization of PTPRJ (also known as DEP1) is regulated by transmembrane domain interactions, and
(ii) disrupting these interactions can antagonize PTPRJ homodimerization, reduce substrate EGFR
phosphorylation, and antagonize EGFR-driven cell phenotypes.
Here, we propose to build upon these new insights along three thematically interconnected, but non-
overlapping, specific aims, with the ultimate goals of: (1) demonstrating that RPTP TM domain interactions are
essential in regulating their activity and substrate access, and (2) developing a new therapeutic approach to
promote RPTP activity against their oncogenic RTK substrates.
In our first aim, we will determine the molecular determinants regulating the heterodimerization of PTPRJ with
EGFR. These studies will be complemented by extending them to understand how PTPRJ TM domain mutants
affect receptor trafficking and ultimate cell outcomes. In the second aim, we will design and select peptides
capable of binding to PTPRJ TM domains and test their ability to disrupt PTPRJ homodimerization, promote
PTPRJ activity against EGFR and other substrate RTKs, and selectively target human tumor xenografts in
mice. In the third aim, we will identify other candidate RTK substrates whose regulation by PTPRJ depends
upon TM domain-mediated heterodimerization, and determine how different cellular contexts predict the cell
signaling and phenotype outcome of interfering with PTPRJ dimerization through TM domains. To do so, we
will implement a systems biology approach based on data-driven computational modeling of phenotypic
measurements and global mass spectrometry measurements of protein phosphorylation and expression in a
panel of cell lines. This aim is motivated by an understanding that all RPTPs have multiple substrates and that
variations in expression of those substrates among cells may lead to different outcomes when PTPRJ
dimerization is disrupted.
Ultimately, the studies proposed here stand to advance both our basic biological understanding of RPTP
biology, which is critically needed, and to lead to new methods to target signaling through oncogenic RTKs that
may be less susceptible to common mechanisms of acquired resistance to RTK inhibitors.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.3389/fonc.2022.1017947
发表时间:
2022
期刊:
FRONTIERS IN ONCOLOGY
影响因子:
4.7
作者:
[Schwarz, Marie, Rizzo, Sophie, Paz, Walter Espinoza, Kresinsky, Anne, Thevenin, Damien, Mueller, Joerg P.]
通讯作者:
Mueller, Joerg P.
Identifying Transmembrane Interactions in Receptor Protein Tyrosine Phosphatase Homodimerization and Heterodimerization.
识别受体蛋白酪氨酸磷酸酶同二聚和异二聚中的跨膜相互作用。
DOI:
10.1007/978-1-0716-3569-8_13
发表时间:
2024
期刊:
Methods in molecular biology (Clifton, N.J.)
影响因子:
--
作者:
[Rizzo,Sophie, Thévenin,Damien]
通讯作者:
Thévenin,Damien
EGFR signaling network adaptations to overcome RAS-induced membrane stress in glioblastoma
-
批准号:10525284
-
项目类别:
-
资助金额:$37.64万
-
财政年份:2022
-
负责人:Matthew J Lazzara
-
依托单位:
EGFR signaling network adaptations to overcome RAS-induced membrane stress in glioblastoma
-
批准号:10703483
-
项目类别:
-
资助金额:$36.43万
-
财政年份:2022
-
负责人:Matthew J Lazzara
-
依托单位:
EGFR signaling network adaptations to overcome RAS-induced membrane stress in glioblastoma
-
批准号:10907884
-
项目类别:
-
资助金额:$16.7万
-
财政年份:2022
-
负责人:Matthew J Lazzara
-
依托单位:
Engineering ERK-specificity for cancer suicide gene therapy
-
批准号:10044569
-
项目类别:
-
资助金额:$41.52万
-
财政年份:2020
-
负责人:Matthew J Lazzara
-
依托单位:
Promoting Receptor Protein Tyrosine Phosphatase Activity by TargetingTransmembrane Domain Interactions
-
批准号:10601618
-
项目类别:
-
资助金额:$6.36万
-
财政年份:2020
-
负责人:Matthew J Lazzara
-
依托单位:
Promoting Receptor Protein Tyrosine Phosphatase Activity by Targeting Transmembrane Domain Interactions
-
批准号:10265510
-
项目类别:
-
资助金额:$39.74万
-
财政年份:2020
-
负责人:Matthew J Lazzara
-
依托单位:
Promoting Receptor Protein Tyrosine Phosphatase Activity by Targeting Transmembrane Domain Interactions
-
批准号:10098384
-
项目类别:
-
资助金额:$40.06万
-
财政年份:2020
-
负责人:Matthew J Lazzara
-
依托单位:
Promoting Receptor Protein Tyrosine Phosphatase Activity by Targeting Transmembrane Domain Interactions
-
批准号:10436341
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2020
-
负责人:Matthew J Lazzara
-
依托单位:
Promoting Receptor Protein Tyrosine Phosphatase Activity by Targeting Transmembrane Domain Interactions
-
批准号:10651834
-
项目类别:
-
资助金额:$39.51万
-
财政年份:2020
-
负责人:Matthew J Lazzara
-
依托单位:
Optimal control models of epithelial-mesenchymal transition for the design of pancreas cancer combination therapy
-
批准号:10450032
-
项目类别:
-
资助金额:$45.23万
-
财政年份:2019
-
负责人:Matthew J Lazzara
-
依托单位:
Optimal control models of epithelial-mesenchymal transition for the design of pancreas cancer combination therapy
-
批准号:10670987
-
项目类别:
-
资助金额:$45.23万
-
财政年份:2019
-
负责人:Matthew J Lazzara
-
依托单位:
Metabolic changes accompanying durable, hypoxia-driven EMT in pancreas cancer
-
批准号:10831307
-
项目类别:
-
资助金额:$16.79万
-
财政年份:2019
-
负责人:Matthew J Lazzara
-
依托单位:
Optimal control models of epithelial-mesenchymal transition for the design of pancreas cancer combination therapy
-
批准号:10218122
-
项目类别:
-
资助金额:$46.16万
-
财政年份:2019
-
负责人:Matthew J Lazzara
-
依托单位:
Quantitative Analysis of ErbB-Targeted-Drug Efficacy
-
批准号:7477429
-
项目类别:
-
资助金额:$2.64万
-
财政年份:2005
-
负责人:Matthew J Lazzara
-
依托单位:
Quantitative Analysis of ErbB-Targeted-Drug Efficacy
-
批准号:6997989
-
项目类别:
-
资助金额:$4.83万
-
财政年份:2005
-
负责人:Matthew J Lazzara
-
依托单位:
Quantitative Analysis of ErbB-Targeted-Drug Efficacy
-
批准号:7117752
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2005
-
负责人:Matthew J Lazzara
-
依托单位:
国内基金
海外基金
登录
查看更多内容
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:32170319
-
项目类别:面上项目
-
资助金额:58.00万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
-
批准号:--
-
项目类别:--
-
资助金额:58万元
-
批准年份:2021
-
负责人:董春海
-
依托单位:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
-
批准号:31672538
-
项目类别:面上项目
-
资助金额:62.0万元
-
批准年份:2016
-
负责人:孙跃峰
-
依托单位:
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
-
批准号:31372080
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:杨迎伍
-
依托单位:
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
-
批准号:81172529
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:杨其峰
-
依托单位:
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
-
批准号:81070952
-
项目类别:面上项目
-
资助金额:35.0万元
-
批准年份:2010
-
负责人:刘师莲
-
依托单位:
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
-
批准号:30672361
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:徐宁志
-
依托单位: